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ABSTRACT
Antibiotic resistance is an ever-growing topic of concern within the medical field causing
researchers to examine the mechanisms of resistance to develop new antimicrobials. Bacteria’s
ability to form biofilms is one mechanism which aids in antimicrobial resistance. Staphylococcus
aureus is of special interest as it is one of the most frequent biofilm-forming bacteria found on
medical devices causing infections and posing dangerous threats in a clinical setting. A recently
developed antimicrobial gel has been shown to have profound effects on treating bacterial
infections and wound healing. This research is centered upon examining the antimicrobial effects
of this gel on the three different stages of biofilm formation in clinical and laboratory strains of S.
aureus. Through a series of experiments examining the effects this gel has on S. aureus at the
stages of biofilm attachment, maturation, and dispersion, the gel has shown significant levels of
inhibition. These findings indicate that the novel gel disrupts biofilm forming processes of S.
aureus, which provides useful information for fighting infections in the medical field. Further
research on the uses and effects of this new gel could lead possibility using the antimicrobial
compound for a variety of clinical purposes.
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I. INTRODUCTION
Biofilms
The resistance of bacteria to antibiotics continues to be a threat on human health, killing
thousands of people each year as a result of infections. A major contribution to antibiotic resistance
is bacteria’s ability to form biofilms. Biofilms are colonies of microorganisms which are held
together by an extracellular matrix, providing homeostasis and allowing them to withstand extreme
and fluctuating environments (1). Biofilm development occurs in three phases: attachment,
maturation, and dispersion. Through a series of reactions, free floating bacterial cells attach and
adhere to a selected surface (2). Upon attachment, bacterial growth of the biofilm occurs as the
cells divide and form micro colonies which cover the surface area (2). As multiple layers of
bacteria are formed on the surface, the biofilm becomes mature and creates a matrix for cell
signaling and distribution (2). Dispersion occurs in response to changes within the environment,
such as a lack of nutrients, allowing bacterial cells to detach to preserve the biofilm (2). Dispersed
cells become free floating cells that can reattach and begin the biofilm development process again
(3). The maintenance of biofilms is due to their extracellular matrix of polymeric substances which
compromises over 80% of the biofilm and is responsible for keeping it intact (2). The matrix has
many roles within the biofilm, most importantly acting as a diffusion barrier, protecting the
organism from harmful substances such as antibiotics (2). This barrier, along with several other
features of the biofilm increases antibiotic resistance and allows infections to persist.
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Staphylococcus aureus
Biofilms, being a leading cause of acute and chronic infections, pose a serious threat in
clinical settings as they are commonly found on medical devices. The leading cause of biofilm
infections is understood to be the Staphylococcus species, as staphylococci make up much of the
normal flora and are found on the surface of the skin (4). Specifically, Staphylococcus aureus can
persist on medical devices through interactions with the surface and human proteins which coat
the device, creating an increasing infection control problem in the healthcare field (5). The
regulation of several key factors has an important role in S. aureus biofilm formation such as the
regulation of attachment factors, exopolysaccharide synthesis, and the accessory gene regulator
quorum sensing system (agr) (4).
S. aureus contains attachment factors which contribute to the attachment of bacteria during
the beginning stages of infection and allow for biofilm development (4). These attachment factors
bind to human proteins like fibrinogen and fibronectin, which cover indwelling medical devices,
increasing colonization of bacteria (4). As the bacterial cell density increases, an agr quorumsensing system recognizes these factors are no longer needed and terminates the expression of
these factors (4).
As staphylococcal biofilms mature, aggregation and structuring of the bacteria occur (4).
Intercellular aggregation within staphylococci is due to the molecule polysaccharide intercellular
adhesion (PIA), which combined with other molecules make up the extracellular matrix of the
biofilm (4). PIA synthesis is of great importance in biofilm formation as it increases the integrity
of the biofilm, resulting in increased virulence of infections (6). Research has found that anaerobic
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conditions significantly increase the production of PIA in S. aureus, therefore increasing PIA
production in biofilms as well due to decreased oxygen levels within the biofilm. (4,6).
In addition to reducing the expression of surface proteins, the agr quorum-sensing system
of S. aureus produces many virulence factors which contribute to staphylococcal growth and
infections (7). Among these is the expression of phenol-soluble modulins (PSM), which are
involved in the development and detachment of biofilms and have fatal effects on the human
immune system (8). The regulation of each of these factors, along with several others, contribute
to the growth of S. aureus biofilms and their persistence in infections.
Previous Research
As technology in the healthcare industry has grown using more medical devices, there has
been a rise of infection rates causing researchers to study biofilm function to develop anti-biofilm
strategies and treatments. Several treatments have shown to prevent and inhibit biofilm growth,
but there has yet to be developed a treatment which eliminates biofilm activity entirely. Previous
research on current antibiotics, the resistance of biofilms to disinfectants, the antimicrobial
properties of hydrogels and topical agents, and new biofilm eradication strategies has added
valuable information to the discussion.
While a vast number of antibiotics exist, few are effective at targeting bacteria within
biofilms. Currently, oxazolidinones and tetracyclines are being used to treat staphylococcal
biofilms as they inhibit protein synthesis (9). Linezolid, the only oxazolidinone approved for
clinical use, works by disrupting the assembly of ribosomes during protein synthesis (9). When
combined with rifampicin, linezolid had bactericidal effects, however it was fount to only be
effective against biofilm infections when administered for long periods of time (9). Research
9

discovered tetracycline antibiotics are most effective in preventing infections, as they prevent the
binding of tRNA during protein synthesis (9). Clinical trials revealed that catheters coated with a
combination of tetracyclines and additional antibiotics had only an 8% colonization, compared to
a 25% colonization of those untreated (9). Despite preventing bacterial growth, gram positive
bacteria have developed a resistance to tetracyclines, thus reducing their effectiveness (9).
In addition, lipopeptides and glycopeptides are antibiotics being used to target the cell
membrane of biofilm bacteria (9). Daptomycin, a lipopeptide which depolarizes bacterial cell
membranes and causes cell death is an alternative antibiotic as S. aureus is becoming resistant to
vancomycin (9). Research studies revealed that daptomycin is more effective in treating
staphylococcal biofilm infections than other antibiotics including clindamycin, linezolid, and
vancomycin as it effectively killed 96% of biofilm bacteria (9). Although S. aureus resistance to
vancomycin is increasing, it continues to be a commonly used antibiotic in treating such infections
(9). The glycopeptide vancomycin inhibits cell wall synthesis by binding to peptidoglycan and
preventing cross-linking (9). The effects of vancomycin eventually lead to cell death, but due to
resistance mechanisms it does not result in complete eradication of biofilm-associated bacteria (9).
Research has also been conducted on the antimicrobial properties of hydrogels and
disinfectants against biofilms as potential treatment options. A study was conducted on the inner
gel of the Aloe barbadensis plant, commonly known as Aloe vera, to examine its antimicrobial
properties as a possible treatment for biofilms. Aloe vera is a common ingredient in many
medicinal products, having over 75 active ingredients found in the inner gel alone, while the leaf
is known to have antibacterial and bactericidal properties (10). The study tested the effects of the
Aloe vera inner gel on Shigella flexneri, a popular bacterium in gastrointestinal illnesses and
Streptococcus pyogenes (10). Research revealed that the bacteria was susceptible to the inner gel
10

of Aloe vera, indicating that these ingredients could be vital for the future development of
antimicrobial products that effectively treat biofilms (10).
Chitosan/dextran based (CD) hydrogels exhibit antimicrobial properties due to chitosan’s
polycationic structure which disrupts the cell membrane of bacteria (11). These hydrogels were
found to lose their bactericidal activity in neutral conditions, so a modified hydrogel was used to
determine how they affected varying types of bacteria (11). The modified hydrogel was created
using N-succinyl chitosan (SC) and dextran aldehyde (DA), which allowed the chitosan to be
soluble at neutral conditions (11). Results showed that the CD hydrogel had bactericidal effects
against E. coli, S. aureus, S. pyogenes, and C. perfringens, and DA was found to be the more
antimicrobial component than SC (11). P. aeruginosa and C. albicans were not affected by the CD
hydrogel, but both were inhibited by high concentrations of the DA component (11). The study
found the binding of the DA component with amino groups of bacterial cell walls was the
mechanism for antimicrobial activity in the hydrogel (11). The DA component contributed to the
research of biofilm treatment and further developed the field, but was not effective against all
bacteria.
Biofilms increased resistance to disinfectants and other antimicrobials has prompted
research to examine what properties of bacterial biofilms contribute to their resistance.
Disinfectants are used on nonliving objects to destroy all bacteria, while antibiotics are used to
treat internal infections and only target specific bacteria (12). While disinfectants can kill all
pathogenic microorganisms, the complex structure of biofilms inhibits biocides from penetrating
through the multiple layers of bacteria, reducing their efficacy (12). A study on the use of chlorine
on P. aeruginosa and K. pneumoniae revealed that only 20% of the chlorine penetrated the core of
the biofilm (13). Also, the components of bactericides are reactive molecules which interact
11

differently with varying bacteria, making them inefficient as a solution for treating all biofilms
(12). The success of disinfectants requires targeting the extracellular matrix to break down these
diffusion and interaction barriers in biofilms, and the use of enzymes is one possible way this could
be done (12).
As the efficacy of antibiotics and hydrogels treating biofilms continues to be a challenge,
new treatment options aimed at eradicating biofilms are being researched. Among the new
strategies being tested is the use of enzymatic treatments to degrade the extracellular matrix and
weaken biofilm structure (9). When this occurs, the bacteria disperse from the biofilm and
antibiotics become more effective at targeting the bacteria (9). Several enzymes including
dispersin B, DNases, and lysostaphin have properties which degrade the polysaccharide matrix,
suggesting that they have the potential to be used as a treatment to prevent and clear biofilm
infections (9).
Another strategy attempting to disrupt biofilms causing them to regain sensitivity to
treatment options is targeting the agr quorum sensing system (9). The agr system is a cellular
communication system that allows the bacteria to share information regarding cell density to
regulate the formation and dispersal of staphylococcal biofilms (9). Research has shown that
activation of the agr system has inhibitory effects on biofilm formation, resulting in increased
levels of proteases and disrupting cell-cell interactions which causes cells to detach from the
biofilm and return to a planktonic state (9). While this approach has proved successful in treating
staphylococcal biofilm infections, it is still being studied as there is a concern that this system may
cause S. aureus to become more invasive (9).
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Antimicrobial Growth Compound
While many strategies and treatments for biofilm prevention and eradication have been
studied, the complexity of their resistance has made it difficult to develop a treatment that is
entirely successful. A newly developed antimicrobial growth compound (AGC), composed of
antioxidants (vitamin C and E) and zinc, has shown profound effects in pain relief and wound
healing. Due to its incredible results, it is believed that this novel gel could have many applications
in the healthcare field, such as being used as an antimicrobial to treat bacterial infections. Previous
research revealed the AGC was not susceptible to Staphylococcus aureus, however these studies
were only performed in liquid cultures. Figure 1 shows the susceptibility of S. aureus to the AGC
compared to other bacteria.

Log10 Colony Forming Units

Incubation of bacteria with 4% Antimicrobial Growth
Compound
16
14
12
10
8
6
4
2
0

Control

Antimicrobial Growth Compound

Figure 1: Incubation of bacteria with 4% Antimicrobial Growth Compound revealing
Staphylococcus aureus most susceptible
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Additional research is needed to study the effects of the AGC on biofilms. As biofilms
contribute greatly to antibiotic resistance, the mechanism of action of how AGC could affect the
development and maturation of biofilms is under investigation. My research is focused on studying
the antimicrobial effects of the novel gel on the three stages of biofilm development, specifically
in Staphylococcus aureus. The results of my research provide new information about this
antimicrobial compound, which can lead to the progression of developing new antimicrobials to
fight antibiotic resistance.

14

II. MATERIALS AND METHODS
The effects of the AGC were examined on the attachment, maturation, and dispersion
phases of S. aureus biofilm development via different methods and assays by measuring the optical
density, crystal violet staining, MTT reduction, and calculating colony forming units. All tests
were performed in triplicate.
Attachment Assay
To observe the effects of the AGC on the attachment phase of S. aureus biofilm
development, a 10% solution of AGC broth was initially added to a 96 well plate containing either
clinical and laboratory strains of S. aureus in lysogeny broth (LB) at an optical density (OD600)
of 0.01 which is equivalent to 1x106 cells/mL. The 10% solution of AGC was prepared by
weighing 10g AGC, adding it to a bottle, and raising the volume to 100mL using LB broth.
Controls of clinical and lab strains of S. aureus in LB without AGC were also added to the well
plate for comparison. The plate was placed in an incubator at 37℃ for 24 hours to allow for biofilm
development. After 24 hours, the plates were removed from the incubator and assayed for OD600,
OD595 after crystal violet staining, OD550 after MTT reduction, and observed for the presence of
colony forming units (CFU).
Optical Density
The OD assay was used to determine the effects of the AGC on S. aureus biofilm density.
To find the OD of the samples, 200 µl of the sample from a well was added to 800 µl of phosphatebuffered saline (PBS), and the absorbance of this solution was measured at 600 nm wavelength.
LB containing 10% AGC was used as the blank.
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Crystal Violet
Crystal violet staining was performed to determine the effects of the AGC on S. aureus
biofilm mass. The liquid from each well was carefully discarded, and then the remaining biofilm
in each well was washed with PBS. Upon removal of PBS, 0.01% crystal violet (200 µl) was added
to each well and removed after 10 minutes. Lastly, 30% acetic acid (200 µl) was added to each
well, and the OD at 595 nm wavelength was measured using a microplate reader. LB only and LB
containing 10% AGC served as the controls.
MTT Reductase
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay determined
the effects of the AGC on the viability of cells, comparing the S. aureus biofilm treated with AGC
to the controls. Viable cells can reduce MTT to formazan, producing a purple color, indicating
how much metabolic activity is present within the biofilm. MTT (20 µl) was added to the biofilm
in each well, and the plate was placed in the incubator at 37℃ for 30 minutes. After 30 minutes,
the plate was removed, and acidic isopropanol (100 µl) was added to each well to stop the reaction
of MTT. A microplate reader was used to measure the OD at 550 nm wavelength of the samples,
with LB only and LB containing 10% AGC as the controls.
Colony Forming Units
The number of colony forming units (CFU) was determined to assess the viability of cells,
or their ability to reproduce. Viable cells, when placed on a culture under special conditions, will
aggregate and reproduce to form colonies of bacteria. To determine the number of colony forming
units present in the AGC treated S. aureus biofilm compared to the untreated, the well contents of
each sample were mixed, and 100 µl of each sample was removed and added to separate mannitol
16

salt agar (MSA) plates. The plates were incubated at 37℃ for 24 hours. After 24 hours, the plates
were removed from the incubator and examined to count the number of colonies present.
Maturation Assay
The effects of AGC on the maturation phase of S. aureus biofilms was examined using the
previously explained technique in the attachment assay, except the 10% AGC broth was added
after the clinical and laboratory strains of S. aureus were added to the well plate and incubated at
37℃ for 2 hours to allow for the development of biofilms. Upon addition of 10% AGC, the well
plate was placed in the incubator at 37℃ for 24 hours. After 24 hours, the OD at 600 nm
wavelength, crystal violet staining, MTT reduction, and colony forming unit assays were
performed using the same methods as described in the attachment assay.
Dispersion Assay
The dispersion phase of S. aureus biofilms and their reaction to the AGC was studied using
the same methods as previously mentioned, but the 10% AGC broth was added after the clinical
and laboratory strains of S. aureus were added to the well plate and incubated at 37℃for 24 hours.
After 24 hours, the 10% AGC was added to each well and the plate was incubated for another 24
hours. The same tests were performed as described in the attachment and maturation assays.
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III. RESULTS
Among all three biofilm phases, the AGC significantly reduced viability of clinical and
laboratory strain S. aureus by assessment through biofilm density, mass, and viability. The AGC
was tested on the attachment phase of biofilm formation by initially adding the gel to clinical and
laboratory strains of S. aureus and evaluating biofilm formation after 24 hours. Image 1 shows the
resulting biofilms established in the well plate after 24 hours. There is a clear visible reduction in
biofilm growth of both the clinical and laboratory strains of S. aureus that were treated with the
AGC at the attachment phase of biofilm formation. The optical density assay showed that the AGC
reduced clinical S. aureus biofilm density by 72% and laboratory S. aureus biofilm density by 66%
at the attachment phase, as shown in Figure 2. The crystal violet assay results shown in Figure 3
revealed that the AGC reduced clinical S. aureus biofilm mass by 96% and laboratory S. aureus
biofilm mass by 87% at the attachment phase.

Image 1: Attachment Phase S. aureus Biofilms (clinical and lab)
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Figure 2: Attachment Phase Optical Density
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Figure 3: Attachment Phase Crystal Violet Staining

S. aureus biofilm viability was greatly reduced by the AGC at the attachment phase as
shown by the MTT reduction and CFU assays in Figures 4 and 5. The MTT reduction revealed a
91% reduction of clinical S. aureus and a 54% reduction of laboratory strain S. aureus, while the
amount of CFU decreased by 96% in the clinical S. aureus and 83% in the laboratory S. aureus
when treated with the AGC. These results indicate that the AGC greatly prevented biofilm
formation of S. aureus at the attachment phase.

19

Biofilm Viability, MTT Reduction Assay
2

OD 570

1.5
1
0.5
0
Clinical SA

Clinical SA+LAV Laboratory SA

Laboratory
SA+LAV

Figure 4: Attachment Phase MTT Reduction
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Figure 5: Attachment Phase Colony Forming Units

Image 2: Attachment Phase Colony Forming Units (top–Clinical S. aureus, bottom-Clinical S.
aureus+AGC)
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The effects of the AGC on the maturation phase of biofilm formation in S. aureus were
tested by adding the AGC after biofilms established for two hours. The reduction effects of the
AGC were not as effective on established biofilms as were preventing biofilm growth by being
adding during the attachment phase, but the results still prove to be significant. The optical density
assay revealed that the AGC caused a 49% reduction of clinical S. aureus biofilm density and 58%
reduction in laboratory S. aureus biofilm density, as shown in Figure 6. The results of the crystal
violet staining (Figure 7) show that the AGC reduced the biofilm mass of clinical S. aureus by
45% and laboratory S. aureus biofilm mass by 37%.
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Figure 6: Maturation Phase Optical Density
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Figure 7: Maturation Phase Crystal Violet Staining

Cell viability was reduced by the AGC significantly when added during the maturation
phase of biofilm formation, as shown by the results in Figures 8 and 9. The MTT reduction assay
showed that the AGC had an 85% reduction in biofilm viability of clinical S. aureus and 86%
reduction for the laboratory S. aureus when added to already established biofilms. When plated on
MSA, the colony forming units revealed the AGC had a 46% reduction in cell viability of clinical
S. aureus and a 37% reduction in the laboratory S. aureus.
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Figure 8: Maturation Phase MTT Reduction
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Figure 9: Maturation Phase Colony Forming Units

The effects of the AGC on the dispersion phase of biofilm formation in S. aureus were
tested by adding the gel after biofilms were established and matured for 24 hours. While there was
not a great reduction in the biofilm density of S. aureus after being treated with the AGC, the AGC
significantly reduced the biofilm viability when added during the dispersion phase. The AGC had
a 47% reduction in clinical S. aureus biofilm density and 32% reduction in laboratory S. aureus
biofilm density when added during the dispersion phase of biofilm formation, shown in Figure 10.
The crystal violet staining assay revealed a 66% reduction in clinical S. aureus biofilm mass and
60% reduction in laboratory S. aureus. Image 3 shows a photograph of the developed biofilms and
the differences between the AGC treated and untreated, during crystal violet staining.
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Figure 10: Dispersion Phase Optical Density
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Figure 11: Dispersion Phase Crystal Violet Staining

Image 3: Dispersion Phase Crystal Violet Staining Plate (top – S. aureus only, bottom - S.
aureus+AGC)
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The MTT reduction assay showed a significant amount of reduction in biofilm viability
when the biofilms were treated with AGC during the dispersion phase of development. Figure 12
shows a 91% reduction in clinical S. aureus biofilm viability and 86% reduction in laboratory S.
aureus biofilm viability. Biofilm viability was also reduced during the dispersion phase as seen in
the CFU assay (Figure 13), with a 62% reduction in CFU in clinical S. aureus and 57% reduction
in CFU in laboratory S. aureus.
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Figure 12: Dispersion Phase MTT Reduction

Image 4: Dispersion Phase MTT Reduction (top rows - S. aureus+AGC, bottom rows - S. aureus
only)
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Figure 13: Dispersion Phase Colony Forming Units
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IV. DISCUSSION AND CONCLUSION
As antibiotic resistance is an ongoing problem in the medical field, the attempt to develop
new drugs and antibiotics that successfully fight infections is crucial. Staphylococcus aureus
biofilms are one of the leading causes of clinical infections and are highly antibiotic resistant due
to their intrinsic properties, making them difficult to treat. A recently developed AGC has had
profound effects when used to treat bacterial infections and wounds, causing us to question how
the AGC would react with cells of S. aureus biofilms. Through a series of experiments testing how
the AGC effects S. aureus biofilm development at three different stages, we discovered the AGC
significantly reduced not only the biofilm’s mass and density, but also the viability of the cells
present.
The AGC had the greatest effects on the attachment stage of biofilm development when
added before the biofilm was able to mature. Therefore, the AGC disrupts the attachment
mechanisms preventing the biofilm from growing and entering the maturation phase. The great
reduction in cell viability reveals how effectively the AGC kills S. aureus cells before biofilm
formation occurs. When the AGC was added during the maturation phase of development, it also
had reducing effects on the biofilm but was not as effective as in the attachment phase. The effects
of the AGC may not be as effective on already established S. aureus biofilms due to the complexity
of the biofilm matrix preventing the AGC from reaching all the cells. The AGC also had reducing
effects on the dispersion phase of development, indicating that the compound inhibited the
dispersive properties. The maturation and dispersion assays which allow S. aureus to grow before
the addition of the AGC indicate the AGC may be bacteriostatic, stopping the bacteria from
reproducing, rather than bactericidal and killing the bacteria present.
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These results add new information to the discussion about infectious biofilms and antibiotic
resistance. S. aureus biofilms are one of the strongest, most threatening group of bacterial
microorganisms for infection, yet this newly developed AGC has shown profound reducing effects
on their biofilm activity. This leads to the need of further research to understand what mechanisms
of action the AGC takes against these cells and how it is successful against such a complex biofilm
structure. Researching the bacteriostatic mechanisms of the AGC, examining the effectiveness of
AGC against polymicrobial biofilms, and testing the AGC in combination with medical devices
are potential future areas Further research on the uses and effects of this new gel can lead to the
possibility of using antimicrobial compound for a variety of clinical purposes in fighting infection
and antibiotic resistance.

28

REFERENCES
1. Hall-Stoodley L, Costerton JW, Stoodley P. 2004. Bacterial biofilms: from the Natural
environment to infectious diseases. Nature Reviews Microbiology 2:95–108.
2. Dufour D, Leung V, Lévesque CM. 2010. Bacterial biofilm: structure, function, and
antimicrobial resistance. Endodontic Topics 22:2–16.
3. Vickery K, Hu H, Jacombs AS, Bradshaw DA, Deva AK. 2013. A review of bacterial biofilms
and their role in device-associated infection. Healthcare infection 18:61–66.
4. Otto M. 2008. Staphylococcal Biofilms. Current Topics in Microbiology and Immunology
Bacterial Biofilms 207–228.
5. Periasamy S, Joo H-S, Duong AC, Bach T-HL, Tan VY, Chatterjee SS, Cheung GYC, Otto
M. 2012. How Staphylococcus aureus biofilms develop their characteristic structure. Proceedings
of the National Academy of Sciences 109:1281–1286.
6. Cramton SE, Ulrich M, Gotz F, Doring G. 2001. Anaerobic Conditions Induce Expression of
Polysaccharide Intercellular Adhesin in Staphylococcus aureus and Staphylococcus epidermidis.
Infection and Immunity 69:4079–4085.
7. Yarwood JM, Schlievert PM. 2003. Quorum sensing in Staphylococcus infections. Journal of
Clinical Investigation 112:1620–1625.
8. Peschel A, Otto M. 2013. Phenol-soluble modulins and staphylococcal infection. Nature Reviews
Microbiology 11:814–814.
9. Kiedrowski MR, Horswill AR. 2011. New approaches for treating staphylococcal biofilm
infections. Annals of the New York Academy of Sciences 1241:104–121.

29

10. Ferro VA, Bradbury F, Cameron P, Shakir E, Rahman SR, Stimson WH. 2003. In Vitro
Susceptibilities of Shigella flexneri and Streptococcus pyogenes to Inner Gel of Aloe barbadensis
Miller. Antimicrobial Agents and Chemotherapy 47:1137–1139.
11. Aziz MA, Cabral JD, Brooks HJL, Moratti SC, Hanton LR. 2011. Antimicrobial Properties
of a Chitosan Dextran-Based Hydrogel for Surgical Use. Antimicrobial Agents and
Chemotherapy 56:280–287.
12. Bridier A, Briandet R, Thomas V, Dubois-Brissonnet F. 2011. Resistance of bacterial biofilms
to disinfectants: a review. Biofouling 27:1017–1032.
13. De Beer D, Srinivasan R, Stewart PS. 1994. Direct measurement of chlorine penetration into
biofilms during disinfection. Applied and Environmental Microbiology 60:4339-4344.

30

